



Fondazione per la Ricerca
sulla Fibrosi Cistica - ETS
fibrosicisticaricerca.it

15th December 2025

**ITALIAN CYSTIC FIBROSIS RESEARCH FOUNDATION - FFC Ricerca
CALL FOR GRANT APPLICATIONS
YEAR 2026**

Summary

1.	Introduction and features of the FFC Ricerca 2026 call.....	2
2.	Priority areas.....	2
3.	General notes and recommendations.....	3
4.	Eligibility criteria	4
5.	Budget	5
6.	Guidelines for filling in the application.....	6
7.	Evaluation of applications	11
8.	Fellowship and research grants.....	12
9.	Awarding and management of research funds.....	12
10.	Scientific and administrative reports, publications	13
11.	Research results, intellectual property and patents.....	13
12.	Writing and submitting applications.....	14
13.	Appendixes.....	14
1.1.	Appendix 1 - The FFC Ricerca facilities.....	14
1.2.	Appendix 2 - How to write a lay summary	16
1.3.	Appendix 3 – List of keywords	17

1. Introduction and features of the FFC Ricerca 2026 call

The Italian Cystic Fibrosis Research Foundation (**FFC Ricerca**) funds research projects that have the ultimate aim to improve the health status of persons with cystic fibrosis (CF) and to provide a breakthrough in the understanding of the molecular basis of the disease.

The relevant features of the call are the following:

- Applicants can submit only one project for this call.
- Principal Investigator (PI) or Coordinator and Partner must have a permanent position; their salary coverage is not provided.
- Applicants can submit projects **lasting 12, 24 or 36 months**.
- The maximum total budget for three options are:
 - **12-months project: 70.000 euros**
 - **24-months project: 130.000 euros**
 - **36-months project: 200.000 euros**.
- For clinical research projects only, the cost for salary coverage can exceed 40% of the entire budget.
- **Deadline** for submitting applications: 12:00 pm (noon) on **4th February 2026**.

FFC Ricerca may fund between 10 and 15 projects, depending on both the type and quality of the applications and the availability of funds.

2. Priority areas

This Call for grant applications aims at funding projects focused on the following 5 priority areas in the field of CF research:

2.1. Understanding and treating CFTR basic defects

Design of new approaches to correct defective CFTR or to compensate for its deficient function with the following particular indications:

- better understanding of CF pathophysiology and comorbidities including those related to aging in pwCF;
- mutation-specific therapies;
- ancillary supports to modulator therapy;
- alternative cellular targets;
- development of therapies based on gene or RNA editing;

2.2. Personalized approaches

Identification and validation of new and appropriate *in vivo* and *ex vivo* models and assays, such as *theratyping*, to predict and monitor the potential efficacy of new therapies finalized to correct the CFTR defect.

2.3. Airway infection in CF

Development of new diagnostic and antimicrobial methods for fast, accurate infection detection and for targeting multi drug resistant or difficult-to-treat pathogens.

2.4. Inflammation in CF

Novel approaches aimed at mitigating inflammation-mediated disease processes.

2.5. Clinical applications and epidemiological studies

- Clinical trials, with special regard to:
 - phase IV clinical studies (post-marketing studies in the real life);
 - studies on prevalence and mechanisms of comorbidities including those related to aging in pwCF;

- studies to improve the outcomes of transplantation in CF;
- studies of efficacy (randomized and controlled phase II/III) are not financed by this call, but FFC Ricerca can contribute by partially co-funding the study. FFC Ricerca reserves the right to discuss this topic on a case-by-case basis.
- innovative diagnostic approaches to predict and monitor the evolution of the disease also in the context of new therapies;
- Epidemiological studies, with a particular focus on:
 - studies monitoring changes in burden of care related to new treatments and the feasibility of reducing the treatment load;
 - studies on the correlation between climate changes, environment and the health of persons with CF.

3. General notes and recommendations

- Research proposals in which **translational objectives** are clearly evident will be prioritized.
- Accordingly, research projects dealing with either **clinical studies or pre-clinical studies** exploiting animal models of CF or performed on primary CF cells culture are encouraged.
- Multicentre projects involving **international partners** and collaborators are encouraged. Please note that researchers working in foreign research centers are admitted to the call and can manage their own project budget, see *Eligibility criteria* and *Budget* session below.
- FFC Ricerca also encourages projects focused on studies on **rare mutations and/or mutations not susceptible to current available modulators**.
- *In vitro* studies dealing with non-CF cell lines are strongly discouraged, unless required for preliminary experiments or used to reinforce data obtained with primary CF cells.
- The study must be supported by preliminary data already acquired; **this call does not fund proof of concepts (PoC)**.
- Researchers should consider the **facilities offered by FFC Ricerca** in the design of the projects presented (see Appendix 1):
 - **Servizio Colture Primarie (SCP)** which collects primary cell cultures obtained from bronchial epithelium of CF and non-CF patients. For further details please visit the dedicated [webpage](#) and contact the service coordinator.
 - **Cystic Fibrosis animal Core Facility (CFaCore)** which develop and provides mouse models for research applications in CF field. For further details please visit the dedicated [webpage](#) and contact the service coordinator.
 - **Cystic Fibrosis Data Base (CFDB)**, the data base of clinical interventions in CF. For further details please visit the dedicated [webpage](#) and write at info@cfdb.eu.
- **FFC Ricerca facilities** (SCP, CFaCore, CFDB) must be considered as a service, therefore the facility coordinators must not be indicated as partner or collaborator. Please see guidelines section *Outside Collaborations/Services* to fill in the Form 9.
- FFC Ricerca encourages **repurposing** studies if there is a strong rationale that demonstrates the validity of the approach in the context of CF pathology.
- Studies aimed at identifying new therapeutic compounds will also be taken into consideration, provided that they suggest new strategies to affect mutated CFTR function and/or CFTR-dependent mechanisms of cell pathology, also including modification of DNA and RNA. Both types of studies may exploit *in vitro* or *ex vivo* primary cell models.

- FFC Ricerca will keep funding *in vitro* and *in vivo* studies addressing effects of drug/compounds not yet tested in CF. The project has to aim at assessing the degree of efficacy and toxicity in CF, possibly addressing the molecular mechanisms of efficacy. Due to funding limitations, FFC Ricerca will not fund "Good laboratory practice" (GLP) compliant preclinical studies for the development of a compound already tested in preclinical studies or to apply for the permission to start a clinical trial. The study can only be partially outsourced to companies in order to collect preliminary data relevant to file a patent application or, alternatively, to submit a request for orphan drug designation (ODD) for the compound under investigation.
- Studies aimed at identifying **new antimicrobial strategies** will only be considered if original strategies are proposed, along with enough preliminary data, to support a potential advantage vs. conventional treatment protocols. FFC Ricerca will not consider studies aimed at the identification or preliminary characterization of hit compounds active against multidrug-resistant pathogens unless a clear advantage over current agents (even at the pre-clinical stage) is expected for treating CF infections.
- Collaboration and transferring of knowledge and expertise from basic to clinical research is particularly recommended. To this aim the advice of a clinical consultant for basic research projects is suggested and her/his role must be clearly highlighted in the application cover letter.
- By "translational research" this call means not only "bench-to-bedside" studies. Research projects considering the translation of results from clinical studies into everyday clinical practice and health decision making are also welcome. Topics to be considered include clinical epidemiology, communication, behavioral science, organizational theory, quality monitoring and quality improvement research.
- The laboratories that will be financed will have to provide the necessary documentation relating to the correct disposal of laboratory waste, as required by D.M. 4/7/2019 (*Adozione delle Linee guida per la redazione del bilancio sociale degli enti del Terzo settore*), by the end of the projects. Further information will be provided to entities deserving funding.

4. Eligibility criteria

- **The PI or Coordinator**, regardless of nationality, must be affiliated with a Host Institution (HI) in a country that contributes patients to the European Cystic Fibrosis Registry (see [ECFS Registry webpage*](#)), with the following conditions:
 - for **PI or Coordinators of Italian HI**: partners and collaborators can be located anywhere in the world.
 - for **PI or Coordinators of non-Italian HI**, at least 1 partner or collaborator of an Italian HI is required.
- *for details please contact: call@fibrosicistricerca.it.
- **Scientists with scientific track record** of at least 3 experimental/clinical papers as first/last/corresponding author in the last 5 years (these papers have to be highlighted with an asterisk in the P.I./Coordinator's curriculum vitae in **Form 6**) are eligible to apply as PI or Coordinator of a multicenter project.
 - **The PI or Coordinator must have a permanent position.** FFC Ricerca will also consider applications from RTD (Fixed-Term) researchers: this type of applicants must meet the criterion of scientific independence providing that their contract **completely** covers the duration of the funding period (a copy of the contract must be submitted).

- Researchers (PI, Coordinator or Partners) who are **retired** or of **retirement age** at the start of the project or reach it during its course cannot be financed by this call, unless they have an assignment/contract from the research institution. If applicable, the documentation certifying the contractual position must be attached in the *Administrative documentation – Upload Area section*.
- **Partners** are those scientists providing an autonomous, active and relevant contribution to a specific part of the project. The FFC Ricerca does not consider Partners those who work in the PI or Coordinator's group or in their laboratory or hospital ward. Individuals involved in supplying biological materials, or clinical and biological data are not eligible as Partners and should rather be enlisted Collaborators.
- **Partners** must have a permanent position. Also RTD (Fixed-Term) researchers are eligible: in that case they must attach a copy of their contract with a declaration of the legal representative of the host institution, as specified above for PI.
- **PI (or Coordinator)** cannot be Partner or PI or Coordinator in other FFC Ricerca projects simultaneously, including projects funded by FFC Ricerca which are in progress, unless they will be concluded on 31st August 2026. A researcher can be a simultaneous partner in no more than two FFC Ricerca projects as long as he/she is not a PI/Coordinator in another project.
- **External collaborators** are researchers with limited roles and functions in the specific project. An external collaborator cannot be involved in more than two FFC Ricerca projects.

5. Budget

The budget description (**Form 11**) must be accurate and every item must be justified and detailed per each research unit and per each year of the funding period. **Inadequate budget description will lead to rejection of the project.** The maximum budget request cannot exceed:

- € 70.000 for one-year projects,
- € 130.000,00 for 2-years projects,
- € 200.000,00 for 3-years projects.

Please note that for clinical research projects, the salary coverage can exceed 40% of the entire budget.

5.1. Eligible costs

- Small research equipment or accessories and software (justified and related to the current project): not more than 7% of the total budget.
- Consumables and animals.
- Fellowships or research contracts (for graduates and technicians). See also point 8 of the Call and also take into account the exception for clinical research projects.
- Travel and scientific meeting participation (international conferences on cystic fibrosis field), training sessions: no more than € 5000 per year.
- Publication expenses, with clear reference to the project funded by this call.
- Costs for patients participating in clinical trials such as insurance coverage and travel costs.
- Overheads (general expenses not provided for in the previous items, but in any case compatible with the admitted expenses): cannot exceed 3% of the total budget. Negotiation on the value of the overheads is possible with foreign research institutions.

- External and occasional professional or technical services for no more than 20% of the total budget). Expenses for clinical consultancy or patentability analysis.

5.2. Ineligible costs:

- Salary for PI, Coordinators, Partners and internal or external collaborators (with the exclusion of personnel above mentioned for FFC Ricerca fellowship or research contract).
- Furniture and stationery articles.
- PC and other hardware.
- Software not specifically related to the project.
- Basic lab or clinical equipment (such as freezers, incubators, ovens, centrifuges etc.).
- Equipment repairing or technical assistance fees.
- Office materials.

6. Guidelines for filling in the application

6.1. Fill in the application forms

The information requested in the application must be correctly reported in the respective forms as below.

Important note: please avoid past/copy of formatted text (such those from PDF files and from the Internet) which could create technical problems in downloading the final PDF of the application. We suggest you copy the text in a .txt file and, then, copy it in the application forms.

- **Form 1 - General information.** Project title, name of the principal investigator, or coordinator for multicentre studies, host institution, project duration (1 to 3 years); type of application (new, resubmitted, renewal of a project both concluded or in progress); research area; keywords that describe the project (as a suggestion, choose a maximum of 5 keywords from the list in Appendix 3); name of the partner/s, their host institutions, names of collaborators (internal and external) really involved in the project (in case of multicentre study specify the collaborators for each research team) and their host institution and specific roles in the project. For each internal collaborator, please provide a brief biosketch. For the external collaborators, the acceptance of collaboration must be supported by a signed personal letter of commitment written on the institutional letter-headed paper reporting his/her contribution to the project (see also *Additional documents*). Also, the main personal data have to be included in the form, both for PI and Partner/s.
- **Form 2 - Project overview (2.500 characters).** It must include: background/rationale, hypothesis and objectives, preliminary results relevant to the project, experimental plan and methods description, timing, anticipated output, relevance for FFC Ricerca mission.
- **Form 3 - Research Plan: Background (3.000 characters), Specific Aims & Rationale (3.000 characters).** The originality of the project must be clear from these items. The cited bibliography must be reported in this section.
- **Form 4 - Preliminary Results (5.000 characters).** They must be proved, convincing and refer to the results obtained by the applicant in preliminary investigations bearing the rationale and the justification of the proposal. The preliminary results will serve to demonstrate that the candidate has the capacity to

carry out the proposed project. This part is regarded as absolutely necessary and decisive for the evaluation of the project. Images and graphs relating to preliminary results must be uploaded in this section as a single PDF document.

- **Form 5 - Experimental Plan and Methods (12.000 characters).** In this part it must be specified in detail: the research plan or clinical protocol, methodology and materials intended to use, justified numerosness of the samples (whether patients or animals) which are going to be examined and the statistical methods that are going to be applied for results evaluation. Moreover, it is requested a description of the development phases of the project, even temporal (timeline), quality controls, and whole pertinent references. Also, the organization and the management to assure quality and feasibility of the project have to be described. Please detail the possible critical points and report any contingency plan (plan B). If applicable, describe in this section a realistic way to valorize the project results in terms of translational research. Gantt chart must be uploaded in this section.
- **Form 6 - Curriculum vitae.** Education and training (3.000 characters), employment and research experiences (3.000 characters), significant publications in the last 5 years (only in peer-reviewed journals). Please indicate with an asterisk the publications in which you are first/last or corresponding author. For multicentre study enclose also Partners' CV and publications of the last 5 years.
- **Form 7 - Roles and Contribution of Coordinator and Partner(s) in the project.** The coordinator has to fill in this part with a detailed description of the specific contribution of each partner in the project. Description of the coordinator's strategies to monitor each team activities, to facilitate communication among one another, to promote exchanges of ideas and methods, to integrate research phases and results must be reported in this form.
- **Form 8 - Features and facilities of the unit.** Laboratory spaces; clinical, IT, laboratory equipment; technologies and services available for the realization of the project must be detailed, indicating their specific relevance to each phase of the experimental plan.
- **Form 9 - Outside Expertises/Services.** Describe the collaborators contribution to the project. External technical services or consultancy/professional services are to be considered. If required, facilities of FFC Ricerca must be reported in this section. External collaborators must provide a personal letter of commitment written and signed on the institutional letter-headed paper to be uploaded in the form *13 - Administrative documentation – Upload Area*.
Note: if advanced SCP services are required, the facility manager must be included among the external collaborators.
- **Form 10 - Lay Summary (3.500 characters).** This must be written both in English and Italian (including the Italian title), in a clear, popular style that is accessible to a broad audience. The lay summary should provide a concise and accurate description of the proposed work, highlighting also its novelty in relation to previous study. If the application is funded, the summary will be published on the FFC Ricerca website, in the Notiziario, and through other communication channels. The summary should clearly highlights the relevance of the proposed study to the mission of FFC Ricerca (to promote innovative treatment and care for CF). Please note that FFC Ricerca may adapt the lay summary, if necessary, to ensure it is fully understandable and aligned with the Foundation's communication objectives. Appendix 2 provides tips to help you write an effective lay summary.

- **Form 11 - Budget.** Specify the expenses both overall and per each year; in case of multicentre study, also per each partner. Any other financial supports must be indicated in this section, reporting the related details (description, amount, project title, granting agency).
- **Form 12 - Cover letter and scientific report.** Upload the Cover letter and the scientific report (if applicable) in this form. The scientific report is required in the case you are asking for the renewal of a project that has already been completed or is about to be completed.
- **Form 13 - Additional documents – Upload area.** Upload all required documents in this form (see the following “*Additional documents*” section). Use the dedicated optional box “Referees” in this form to provide any name of reviewers to suggest or to exclude, please indicate name, surname, affiliation and email.
- **Form 14 - Validate and Download PDF.** This section will highlight in red any empty fields or errors that can occur in filling the forms. By clicking on the red fields, the system opens the section that needs to be filled out. Download the application in PDF format by clicking on the “Download/print this project” button (at the left of the page). **You can validate and download the application in PDF format at any stage.** Once the application is completed (no errors are highlighted), click on “Validate and send” to complete the submission and send the application to FFC Ricerca’s Scientific Direction.

6.2. Additional documents (See Forms 12 and 13 in the application platform)

6.2.1. Cover Letter

Each project must be accompanied by a cover letter that summarizes the overall project plan and the reasons why it falls within the priorities indicated in the call for applications, in line with the Foundation's mission objectives and why it is believed that FFC Ricerca should consider the project worthy of funding. If applicable, in the cover letter the applicant must declare (specifying the details) any **patent application**, or granted patent, claiming an invention related to the proposed project.

In case of **resubmitted projects** (previously submitted to FFC Ricerca and not approved), the cover letter must also include detailed, point by point, reply to the critiques of the referees if the previous application underwent full review.

Resubmitted projects require extensive explanation and cannot be resubmitted with only minor tweaks. A project can be resubmitted only once even if the proponent is different.

For **Renewal projects** the scientific report must be included (by attaching it in the appropriate box in Form 12). The scientific report must include the details of the project’s achievements, the contribution of each Partner (for multicentre projects) and a list of the resulting publications and congress presentations (abstracts).

Cover letter and scientific report (applicable only for Renewal projects) must be uploaded in the **Form 12**.

6.2.2. Individual project

Documents required for individual project:

- acceptance by the host Institution of the PI;
- copy of the contract and its duration (see point 2), in case the PI or Partner has no permanent position;
- consent for use of personal data, according to GDPR and the Italian Law 196/2003;

- signed declaration of commitment by each internal and external collaborator involved in the project reporting his/her contribution to the project. A single pre-compiled form to fill in with the names and signatures of all internal collaborators is also available in the “Administrative documentation - Upload Area” of the platform;
- each external collaborator must provide in the “*Administrative documentation - Upload Area*” a personal letter of commitment written and signed on the institutional letter-headed paper;
- PI declaration of adherence to provisions governing laboratory animal care, if applicable.

6.2.3. Multicentre Project

The coordinator of a multicentre project is the only responsible for both the accuracy and the completeness of all the documentation submitted to the Italian CF Research Foundation (including those of partners’ centres). Researchers (coordinator or partner) working in foreign institutions can manage their own project budget in accordance with specific agreement with FFC Ricerca issued after the possible funding (see *Eligibility criteria* and *Budget*).

Coordinator: see documents required for individual project.

Partners: each partner has to transmit to the coordinator (who will send them to FFC Ricerca) the following documents:

- acceptance of partnership (along with personal data and consent to use them, address, telephone and fax number, e-mail);
- copy of the contract, in case of not permanent position or foreseen retirement;
- declaration of acceptance by the host institution;
- partner’s declaration of adherence to provisions governing laboratory animal care, if required;
- signed declaration of commitment by each internal and external collaborator involved in the project reporting his/her contribution to the project. A single pre-compiled form to fill in with the names and signatures of all internal collaborators is also available in the “*Administrative documentation - Upload Area*” of the platform.
- each external collaborator must provide in the “*Administrative documentation - Upload Area*” a personal letter of commitment written and signed on the institutional letter-headed paper;

6.2.4. Clinical project

Projects that fall into this area of intervention must be clearly patient oriented. They must include, even just in part, diagnostic, therapeutic or rehabilitative interventions on humans, not provided for in common standard or from the personal plan of diagnosis, care and rehabilitation.

6.3. Documentation

According to the type of study, a clinical project must **provide documentation** in accordance with the current law:

- Clinical Trial**: Regulation (EU) n. 536/2014
- Medical Device*: Regulation (EU) n. 745/2017 and Regulation 746/2017
- Observational Study*: Ministerial Decree of 30.11.2021 and (Italian Official Gazette G.U. No. 76 of 31 March 2008.

** The evaluation, authorization, and supervision of clinical trials are the responsibilities of EU Member States and European Economic Area (EEA) countries via the Clinical Trials Information System.

*Ethical Committee Approval (for each partner/centre, if multicentre study) to be sent to FFC Ricerca after award as soon as possible;

- Informed consent form (for interventions and for use of personal data, in anonymous form, for research purpose, released by patients or people involved in the study) plus patient information leaflet;
- Good Clinical Practice declaration by the applicant.

6.3.1. Methods and data management

For the preparation of a clinical application, FFC Ricerca strongly suggests to follow the procedures provided by the main international checklists, such as:

- CONSORT (for randomized studies)
- STROBE for observational studies)
- STARD (for diagnostic studies)
- PRISMA (for systematic reviews)

Further information are also available at the link of the [Equator Network Initiative](#).

Multicenter clinical studies are advised to use a web-based Case Report Form (CRF). Data management and monitoring could be more appropriately supplied by a Contract Research Organization (CRO). Given the relevant cost of CROs, FFC Ricerca could propose one which has been assessed as reliable and cost-efficient. Costs and agreement with the CRO have to be reported in the budget.

6.3.2. Projects including use of animal models

Any project which includes experiments on animals must be accompanied by a specific authorization of the Ethical/Technical Committee of the Institute hosting the animal facility to be submitted after award of the grant and not later than 31st December 2026.

Moreover, the PI or coordinator must declare that the procedures concerning those experiments will follow the instructions included in the legislative decree 2014, n. 26, “Attuazione della direttiva 2010/63/UE sulla protezione degli animali utilizzati a fini scientifici (14G00036) (GU n. 61 del 14- 3-2014)”.

NOTE: *If the approval of Ethical Committee (for clinical trials) or Ethical / Technical Committee (for animals) and “Parere Unico” are not available by 31st December 2026, a follow-up report on the ongoing application either to the Italian Ministero della Salute or the Local Ethical Committee must be sent to this Foundation by email. Providing this information to the FFC Ricerca Foundation is crucial for the correct management of the grant.*

6.3.3. Resubmitted projects

Researchers who are going to resubmit a project previously not funded by FFC Ricerca, even with a different title and improvements, must follow these recommendations:

- The **cover letter** must highlight the year of the previous submission and the relevant modifications of the revised one.

- If the previous application underwent full review, the cover letter must also include detailed, point by point, reply to the critiques of the referees and FFC Ricerca Scientific Board.
- In case the revised application is submitted by a different PI, an explanation must be provided in the cover letter.
- The same research project can be resubmitted only once, even if substantially modified and even by a different proponent.

6.4. Submission by former FFC Ricerca grant recipients

A former FFC Ricerca grant holder may submit a new project or a proposal of development of a project already funded by FFC Ricerca (“Renewal project”). In both cases all of the following must apply:

- The previous project has been completed and its final scientific report has been already submitted to FFC Ricerca. The scientific report must include details of the project’s achievements, the contribution of each Partner (for multicentre projects) and a list of the resulting publications and congress presentations (abstracts).
- Coordinators or partners in a multicentre project financed by FFC Ricerca may submit a new research proposal as PI or Coordinator provided their previous projects were completed or that the ongoing project expires on 31st August 2026, and that they are not involved in other FFC Ricerca projects.

7. Evaluation of applications

Important note: incomplete or behind schedule applications will not be processed for evaluation.

Procedure of evaluation

Grants will be awarded on a priority basis. Specific factors that will play a major role in determining a successful outcome of the application are:

- relevance to the Italian CF Research Foundation’s mission and to the priority areas;
- soundness and originality of the study;
- relevance of the preliminary results;
- the potential value to improving the clinical and care strategies;
- the potential value to stimulating further studies, mainly on translational basis;
- the appropriateness of the design of the study;
- the scientific record of the participants;
- methods reliability*;
- feasibility within the duration of the project;
- facilities appropriateness;
- clarity and quality of lay summary.

*For projects involving people with CF, healthy individuals or animals, their number and the consequent statistical analysis will be taken into strong consideration.

All accepted applications will undergo a preliminary review by the Scientific Committee of the Italian CF Research Foundation on the basis of their relevance to the Foundation’s mission and overall quality. Projects selected in this triage step will undergo full peer-review by an international panel of experts. In the final step, the projects will be evaluated by the

Scientific Committee, taking in due consideration the independent referees' comments. The Scientific Committee will also review the research activities related to the required budget and the project duration. **If the proposed activities and the budget are not considered consistent with the duration, the project will be rejected. The evaluation of the Committee is final, with the approval of the Board of Governors.**

Due to the competitive nature of project selection, projects that have received a positive evaluation by the external reviewers may be denied funding. Co-funding of projects must be declared and accurately described in the appropriate section of the application (see Form 11).

8. Fellowship and research grants

Below are reported the indications regarding the budget requests for fellowships and important notes for the personnel involved in research activities.

- Cost for salaries cannot exceed 40% of the total amount of the grant, with the exception for clinical research projects.
- Clinical research projects can apply for more than one contract per year for the entire duration of the project and the related costs can exceed 40% of the required budget. Please consider a maximum cap of 31.000 euro per year for graduated personnel.
- FFC Ricerca also recalls that the project must be conducted mainly with the direct involvement of PI/Coordinator, partners and internal and/or external collaborators as indicated in the application.
- The life of the research grant (including the part concerning scholarships and contracts) cannot exceed the duration of the project and will expire at its end date.
- FFC Ricerca will directly manage the research grant (including scholarship or contract). Exceptionally, other modes of administration of the grant and research collaborators must be discussed with the FFC Ricerca. On assignment of the grant, FFC Ricerca will provide to the PIs or Coordinators detailed information about the procedure to follow.
- Fellows or contract holders have to be mentioned in any documents or publications as "Italian CF Research Foundation fellow/contract holder". The FFC Ricerca reserves the right to have direct contacts with the fellows or contract holders and to ask for periodical progress reports on their work in the project.
- Principal Investigators/Coordinator, Partners and fellows or contract holders must participate in the annual convention of the Italian CF Researchers as FFC Ricerca guests. The attendance to the annual Convention is mandatory because it is a working time on research funded by FFC Ricerca and not just a general update conference.

9. Awarding and management of research funds

The awarding of funds will be formally decided by the FFC Ricerca Board of Governors and communicated on assignment. As a rule, funds are allocated to the PI, not to the Institution where he/she intends to carry out the funded project.

The FFC Ricerca will manage directly the funds according to the PI's or Coordinator's indications. Approved PI/Coordinators and Partners have to keep an accurate and update account, in parallel to CF Foundation. With reference to budget indications, expenses will be administered per year and per each partner centre.

In case of 2-year or 3-years projects, award recipients will be expected to provide a detailed yearly administrative report by the end of September to obtain subsequent payments.

Any changes of the original destination of budget formalized on assignment, occurring during the fulfillment of the project, must be exceptional and formally asked and agreed with FFC Ricerca.

In the case of funding to non-Italian research institutions, the management of the funds will be indirect. The grant will be transferred to the funded institution following the definition of an agreement for the transfer of funds.

FFC Ricerca will not pay any expenses made after the date of conclusion of the project or exceeding the budget assigned. No expense orders can be issued in the last month of the project. Any costs in excess of the budget will be charged personally to the PI or Coordinator.

10. Scientific and administrative reports, publications

At the end of each year of activity the PI must provide a detailed scientific and administrative progress report, which is necessary to decide the continuation of the funding. At the end of the project, the investigators are invited to submit, together with the administrative report, a final scientific report including any publications and congress presentation abstract referring to the project. Any publication or congress abstract relevant to the project must be forwarded to the Foundation before such reports to be published.

No publication or dissemination of the results of ongoing research should jeopardize the future patenting of any research results as a form of pre-dissemination.

The Fondazione per la Ricerca sulla Fibrosi Cistica/FFC Ricerca must be acknowledged in all publications deriving from the funded project (congress abstracts, book chapters, scientific articles, congress slides, press releases, etc.) specifying the code of the relative grant and by inserting the FFC Ricerca logo both on the slides and the posters of the congress. Furthermore, the adopters of a project, as indicated by FFC Ricerca, have to be mentioned (see [Research project - I progetti di Ricerca](#)).

If the FFC Ricerca's facilities have been used, they must be cited in the acknowledgements. If the contribution of the managers or researchers belonging to the foundations' facilities is relevant for the publication, they must be reported among the authors.

FFC Ricerca may ask investigators to collaborate to public commitment and dissemination of the results of their research in order to support the fundraising of FFC Ricerca. To this end, it is up to FFC Ricerca to contact the investigators.

11. Research results, intellectual property and patents

One of the main goals of FFC Ricerca is to translate research findings into clinical applications available to CF patients; this can be achieved by partnering with the industry, so that the most promising research results can be fully developed into therapies, devices and diagnostics.

FFC Ricerca requires that all scientific results derived from projects funded by FFC Ricerca, which hold the potential for a possible development, are carefully evaluated for the purposes of intellectual protection and/or commercial valorization.

Funded scientists must promptly notify FFC Ricerca in writing of the intention to file any patent application and to enter into an agreement with for-profit entities for the exploitation of results obtained from research funded by FFC Ricerca.

The filing of a patent application relating to results from projects funded by FFC Ricerca must first be discussed with and authorized by FFC Ricerca. The dedicated institutional offices of the funded investigators (TTOs - Technology Transfer Offices) can provide support and assistance on intellectual property matters and technology transfer activities.

In any case, the intention to file a patent application must be previously communicated to FFC Ricerca, in time to allow negotiations between TTOs of the PI's/Collaborators Institutions and FFC Ricerca regarding evaluation of the expenses incurred by each of them and the percentage of ownership of the patent of each of the parties, both in term of expenses to sustain and in terms of possible future revenues. The relevant agreement with the funded scientists' institutions shall be negotiated by the parties in good faith.

FFC Ricerca reserves the right to participate in the ownership of any know-how, intellectual property and inventions derived from funded projects, proportionally to its investments.

FFC Ricerca is confident that funded researchers will operate with transparency and honesty regarding the attribution of relative merit to any work, invention or discovery. Researchers must always remember that all funds supporting CF research are raised through voluntary donations.

12. Writing and submitting applications

Applications must be written in detail and submitted only through the dedicated online platform <https://forms.fibrosisticaricerca.it/en/>, other options are not accepted. For first time access a registration is required to create a personal account and allow applications submission. Attention must be paid to not exceed the indicated number of characters in each form. Any images (photos, graphs, tables) must be low-resolution version and uploaded in one single PDF that must be attached in each specific section of the platform if required.

Deadline: the applications must be submitted through this platform **by 12:00 pm (noon) on February 4th, 2026.**

13. Appendixes

13.1. Appendix 1 - The FFC Ricerca facilities

Note: in the case of a publication, if FFC Ricerca facilities have been used, they must be cited in the acknowledgements and the respective managers must be informed. If the contribution of the managers or researchers belonging to the facilities is relevant for the publication, they must be reported among the authors.

13.1.1. SCP – Primary Cell Facility (Servizio Colture Primarie)

Established in 2012 the primary cell facility, born from the collaboration between the FFC Ricerca and the Gaslini Institute in Genoa, provides a collection of **cell cultures obtained from bronchial epithelium of both CF patients and non-CF** control subjects to CF researchers. The bronchi, from which the cells are isolated, come from the transplant center in Milan.

The **aims** of the facility are:

- the study of the pathophysiology of cystic fibrosis.
- the evaluation of therapeutic strategies.

The **cells and available services** are:

- collection of primary bronchial cultures isolated from bronchi of explanted lungs from individuals undergoing lung transplantation (CF patients or subjects transplanted for other pathologies);
- protocol for the correct cultivation of the submitted cells;
- training in SCP's laboratories.
- advanced tests depending on researchers requests and the expertise acquired by the lab.

The following is a list of cells **genotypes** available in the facility:

F508del/F508del	F508del/3878delG	N1088D/G542X
F508del/G542X	F508del/1874insT+Y577F	N1303K/2183AA>G
F508del/R1162X	F508del/L927P	N1303K/711+5G>A
F508del/1717-1G>A	F508del/C276X	R1006C/M1V
F508del/N1303K	F508del/L1077P	R1158X/3849 +10KbC>T
F508del/R553X	F508del/2789+5G>A	R1162X/2789+5G>A
F508del/CFTRdelE 17A-18	F508del/Q552X	R1162X/3849+10KbC>T
F508del/3849+10KbC>T	G542X/711+5G>A	del Ex 22-23-24/UK
F508del/62+1G>T	G542X/H609R	1525-1G>A/G458R
F508del/G85E	G542X/1717-1G>A	2789+5G>A/M1V
F508del/2184insA	I502T/N1303K	2789+5G>A/R1070Q
F508del/1259insA		

For further information, please write to: serviziocoltureprimarie@fibrosicisticaricerca.it.

13.1.2. CFaCore - Cystic Fibrosis animal Core Facility

Established in 2009, CFaCore is a specialized research facility providing pre-clinical services to CF researchers. Located at San Raffaele Hospital in Milan, it operates within a dedicated infrastructure, including the Infections and Cystic Fibrosis Unit and an animal facility with Biosafety Level 2 (BSL2). The core facility manages CF murine colonies and conducts pre-clinical research to advance new treatments for CF.

Key services are offered:

- management and distribution of transgenic cystic fibrosis mice, ensuring their well-being for experimental purposes;
- scientific and regulatory support to plan pre-clinical studies and prepare documentation for ethical approval;
- pre-clinical models of acute and chronic respiratory infections and inflammation established with reference and clinical CF-related pathogens along with associated virulence factors such as LPS;
- execution of experimental protocols including the administration of systemic or aerosol pharmacological treatments according to specific short or long-term schedules;
- analysis of pathogen and host responses, incorporating lung function measurements to generate comprehensive results;
- definition of milestones and project goals to drive efficient progress and ensure the successful achievement of overall objectives.

For further information, please contact CFaCore coordinator Dr.ssa Alessandra Bragonzi, Infections and Cystic Fibrosis Unit, San Raffaele Scientific Institute; bragonzi.alessandra@hsr.it.

13.1.3. CFDB - Cystic Fibrosis DataBase - www.cfdb.eu

Established in 2011, the CFDB is a web-based, free access tool for health care professionals, researchers and students to evaluate in real time what are the current evidences about clinical efficacy of interventions in CF.

The CFDB collects more than **1,300 studies divided in 8 sections**, including Cochrane reviews, Cochrane protocols, DARE, HTA and Economic reviews, published RCT, published non-RCT, congress abstracts and ongoing trials. In addition, CFDB collects **50 thematic worksheets**, named *Topics*, on relevant clinical subjects in CF that critically summarize the state of the art of available evidences.

The objective of CFDB is to classify clinical studies to get answers to specific questions:

- which interventions are effective, in which groups of CF patients and for which outcomes?
- to what extent do the results of the literature allow to make decisions for specific clinical issues? What issues need to be studied further?

This tool may help clinicians, researchers, students to have a faster updated view of clinical research in CF by using queries on the main topics in CF care. It could also be helpful to anyone going to design new studies, as it provides a concise description of what is currently known and what issues, on the contrast, need additional research.

What can you do with CFDB?

- You can build a query, selecting terms from search menus;
- You can also select one or more citations and read the details of the studies;
- You can read updated summaries (Related topics) on the state of the art of the most relevant topics in CF.

For further information, please contact CFDB coordinator Roberto Buzzetti at robuzze@gmail.com.

13.2. Appendix 2 - How to write a lay summary

What is a lay summary?

A lay summary is a **brief paragraph about your research project**. It explains complex ideas and technical terms to people who do not know about the subject, or a **lay audience**. The audience of FFC Ricerca includes everyone from non-specialists in your field to volunteers, patients, caregivers and the general public.

The lay summary scheme

The lay summary should be no longer than 3500 characters with spaces included, and should consist all of the following sections and questions to answer:

- *Title (only in the dedicated space of the form)*
- *Lay Title [pleas avoid acronyms, e.g. cystic fibrosis not CF] (only in the dedicated space of the form)*

- *What is your scientific question?* [max 300 characters with spaces included]
- *Why is this important?* [max 700 characters with spaces included]
(Explain the impact of the work, what is going to change)
- *How will you conduct the research?* [max 700 characters with spaces included]
(Methodological information of how you will carry out your research project)
- *What do you hope to achieve?* [max 700 characters with spaces included]
(Summary of the most important anticipated results)
- *What are the implications of your research for persons with cystic fibrosis? Are there any reasons for caution?* [max 700 characters with spaces included]
- *Future perspectives* [max 400 characters with spaces included]

Instructions to authors:

- Make the summary easy to read and interesting. Don't oversimplify. While trying to make it simple, ensure that the crux of your research is not missed out. The reader must clearly understand what the research is about and how it will affect the society.
- Attempt to keep the 'reading age' of your summary at high school level.
- Use first person and active voice ("we agreed" rather than "it was agreed").
- Use positives not negative sentences.
- Keep sentences short, clear and focused.
- Do not overstate the importance/relevance of your study. Place it honestly within the existing literature and how the study adds to current knowledge.
- Avoid jargon and scientific abbreviations (e.g. FEV1) unless absolutely necessary. Technical terms and complex mechanisms/measurements need to be thoroughly explained using basic terminology. Acronyms should be used sparingly and must be spelled out on first reference.

13.3. Appendix 3 – List of keywords

In the appropriate section of Form 1 - General information, briefly describe the project using the following keywords list as a suggestion. Choose a maximum of 5 keywords.

1. Modulator Therapies	22. Diabetes
2. Gene therapy	23. Orphan mutations
3. <i>Pseudomonas aeruginosa</i>	24. Neonatal screening
4. Non-tubercular mycobacteria (NTM)	25. <i>Aspergillus fumigatus</i>
5. Psychological aspects	26. Metabolomics
6. Epidemiology	27. Biomarkers
7. Anti-inflammatories	28. Genomics
8. Mouse models	29. CF alternative targets
9. Cell models	30. Microbiome
10. Theratyping	31. CFTR and basic defect
11. Other experimental models	32. Autophagy
12. Proteomics	33. Multiresistance
13. Interactomics	34. Clinical studies and translational medicine
14. Lipidomics	35. RSV - Respiratory syncytial virus
15. Bioinformatics	36. Electrophysiology
16. Mitochondria	37. Chronic obstructive pulmonary disease (COPD)
17. Phagic therapy	38. Lung transplantation
18. Gene modifiers	39. Pharmacology
19. Mucolytics	40. Lung Disease
20. <i>Burkholderia cenocepacia</i>	41. Bone disease
21. Imaging	42. Liver disease